Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,442 across all filing types
Latest filing 2020-02-12 Regulatory Filings
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Ceasing to be a substantial holder 2 pages 89.9KB
Regulatory Filings Classification · 100% confidence The document contains only placeholder text and omitted images, with no substantive content or financial data. The length is very short (192 characters), and there is no indication of any report, announcement, or filing type. Given the lack of content, this document does not fit any specific report category and defaults to the fallback category for miscellaneous filings.
2020-02-12 English
Appendix 4C - quarterly 7 pages 354.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities and Cash Flow Report Quarter ended 31 December 2019' and includes detailed financial data such as cash flow statements, cash equivalents, financing activities, and estimated cash outflows for the next quarter. It references compliance with Listing Rule 4.7B and includes an Appendix 4C, which is a standard quarterly report format for entities listed on the ASX. The document contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement or a brief summary but a comprehensive quarterly financial report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2020
2020-01-30 English
Imugene PD1-Vaxx Immunotherapy Update 2 pages 136.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on the clinical development of Imugene's PD1-Vaxx immunotherapy. It discusses milestones such as GMP manufacturing completion, preclinical toxicology studies, and plans for a Phase 1 clinical trial. There are no financial statements, earnings data, or detailed financial analysis present. The content focuses on clinical development progress and regulatory milestones rather than financial results or management commentary. The document length is about 5754 characters, which is relatively short and reads like a corporate announcement rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS), which is a general category for regulatory announcements and updates that do not fit other specific categories.
2020-01-27 English
Imugene HER-Vaxx Immunotherapy Patent Granted in US 2 pages 122.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about Imugene Limited receiving a patent grant from the United States Patent and Trademark Office for their HER-Vaxx immunotherapy. It is a short announcement (3454 characters) focused on the patent grant milestone, with no financial data, no detailed report, or regulatory filing content. It does not contain financial statements or management discussion. It is not a report publication announcement since it does not mention any report being attached or published. The content is a regulatory announcement about intellectual property rights, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-01-13 English
Completion of Less Than Marketable Parcel Sale 1 pa
Transaction in Own Shares Classification · 95% confidence The document is an ASX release announcing the completion of a share sale program for holders of Less Than Marketable Parcels (LTMP). It details the number of shareholders involved, shares sold, sale price, and the effect on the shareholder count. There is no financial report, earnings data, management discussion, or regulatory certification. The content is an update on a capital-related transaction but does not describe new financing or capital raising activities, rather it reports on the completion of a share sale program to reduce administrative costs. This fits best under the category of Transaction in Own Shares (POS), as it involves the company facilitating the sale of its own shares held by small shareholders.
2019-12-23 English
Appendix 3B and Required LR 3.10.5A Information 15 pages 559.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement detailing the completion of a private placement capital raising by Imugene Limited. It includes extensive information about the number and class of shares issued, issue price, shareholder approval under listing rules, dilution effects, and other details related to the issuance of new shares and options. The presence of an Appendix 3B form, which is a standard new issue announcement form required by the ASX, confirms this is a capital raising and share issuance announcement. There are no financial statements or management discussion of financial results, so it is not an Annual Report or Interim Report. It is not a regulatory certification or voting result announcement. The document is focused on capital structure changes and fundraising activities. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence score.
2019-12-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.